SCHEMBL2538821

SCHEMBL2538821

CCOc1cc(C(Oc2ccc(C(=N)N)cc2)C(=O)NCc2ccccc2S(=O)(=O)C2CC2)ccc1OC(C)C

nearest known ligand 0.58

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ F7 P08709 20/20 0.58
▸ F3 P13726 13/20 0.58
▸ F2 P00734 12/20 0.58
▸ F10 P00742 10/20 0.58
▸ F11 P03951 6/20 0.58
▸ PRSS1 P07477 4/20 0.45
▸ PRSS2 P07478 1/20 0.39
▸ PRSS3 P35030 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL15643025 0.95 F7 (0.54) F7F3F2F10F11
SCHEMBL4147786 0.85 F7 (0.47) F7F3F2F10F11
SCHEMBL2536769 0.83 F7 (0.64) F7F3F2F10F11
SCHEMBL2544810 0.81 F7 (0.75) F7F3F2F10F11
Trifluoroacetic Acid SCHEMBL2543814 0.81 F7 (0.45) F7F3F2F10F11
SCHEMBL2539326 0.79 F7 (0.59) F7F3F2F10F11
Trifluoroacetic Acid SCHEMBL2538019 0.79 F2 (0.59) F7F3F2F10F11
SCHEMBL15643026 0.79 F7 (0.45) F7F3F2F10F11
Trifluoroacetic Acid SCHEMBL15642948 0.78 F7 (0.69) F7F3F2F10F11
SCHEMBL2536503 0.76 F7 (0.56) F7F3F2F10F11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996541-B1 2-(ARYLOXY)ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL MYERS SQUIBB CO (US) 2014-04-23 — — EP claimed
US-8044242-B2 2-(aryloxy) acetamide factor VIIa inhibitors useful as anticoagulants BRISTOL-MYERS SQUIBB COMPANY (US) 2011-10-25 — — US claimed
EP-1996541-A1 2-(ARYLOXY)ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS Bristol-Myers Squibb Company (US) 2008-12-03 — — EP claimed
WO-2007103996-A1 2-(ARYLOXY)ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-09-13 — — WO claimed
US-8044242-B2 2-(aryloxy) acetamide factor VIIa inhibitors useful as anticoagulants BRISTOL-MYERS SQUIBB COMPANY (US) 2011-10-25 — — US disclosed
US-20090131473-A1 2-(ARYLOXY) ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY 2009-05-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131473-A1 2-(ARYLOXY) ACETAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS F7, F9, F12 F7 1/4885F3 11/4885F2 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback